An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects

Trial Profile

An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Rifampicin
  • Indications Cardiovascular disorders; Tuberculosis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Actual end date changed from Apr 2013 to Dec 2012 as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top